Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration

Intensive Care Medicine

Volumn 41, Issue 1, 2015, Pages 103-110

  De Pascale, Gennaro ^a   Fortuna, Serena ^a   Tumbarello, Mario ^a   Cutuli, Salvatore Lucio ^a   Vallecoccia, MariaSole ^a   Spanu, Teresa ^a   Bello, Giuseppe ^a   Montini, Luca ^a   Pennisi, Mariano Alberto ^a   Navarra, Pierluigi ^a   Antonelli, Massimo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Continuous infusion; Linezolid; Pharmacokinetics; VAP

Indexed keywords

CREATININE; LINEZOLID; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTINUOUS HEMODIAFILTRATION; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; EPITHELIUM; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MINIMUM PLASMA CONCENTRATION; OBESITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIMPLIFIED ACUTE PHYSIOLOGY SCORE; VENTILATOR ASSOCIATED PNEUMONIA; AGED; COMPARATIVE STUDY; COMPLICATION; CRITICAL ILLNESS; DRUG MONITORING; INTRAVENOUS DRUG ADMINISTRATION; ITALY; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; ORGAN DYSFUNCTION SCORE; PNEUMONIA, VENTILATOR-ASSOCIATED; RISK ASSESSMENT;

ACETAMIDES; AGED; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; DRUG MONITORING; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OBESITY; ORGAN DYSFUNCTION SCORES; OXAZOLIDINONES; PNEUMONIA, VENTILATOR-ASSOCIATED; PROSPECTIVE STUDIES; RISK ASSESSMENT; ROME;

EID: 84918580244     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-014-3550-y     Document Type: Article

References (32)

1. De Pascale G, Bello G, Tumbarello M, Antonelli M (2012) Severe pneumonia in intensive care: cause, diagnosis, treatment and management: a review of the literature. Curr Opin Pulm Med 18:213–221
2. Vincent JL, de Souza Barros D, Cianferoni S (2010) Diagnosis, management and prevention of ventilator-associated pneumonia: an update. Drugs 70:1927–1944
3. Meyer E, Schwab F, Schroeren-Boersch B, Gastmeier P (2011) Increasing consumption of MRSA-active drugs without increasing MRSA in German ICUs. Intensive Care Med 37:1628–1632
4. Choi EY, Huh JW, Lim CM, Koh Y, Kim SH, Choi SH, Kim YS, Kim MN, Hong SB (2011) Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia. Intensive Care Med 201137:639–647
5. Nguile-Makao M, Zahar JR, Francais A, Tabah A, Garrouste-Orgeas M, Allaouchiche B, Goldgran-Toledano D, Azoulay E, Adrie C, Jamali S, Clec’h C, Souweine B, Timsit JF (2010) Attributable mortality of ventilator-associated pneumonia: respective impact of main characteristics at ICU admission and VAP onset using conditional logistic regression and multi-state models. Intensive Care Med 36:781–789
6. Bassetti M, Trecarichi EM, Mesini A, Spanu T, Giacobbe DR, Rossi M, Shenone E, Pascale GD, Molinari MP, Cauda R, Viscoli C, Tumbarello M (2012) Risk factors and mortality of healthcare-associated and community-acquired Staphylococcus aureus bacteraemia. Clin Microbiol Infect 18:862–869
7. Bouza E, Giannella M, Bunsow E, Torres MV, Granda MJ, Martín-Rabadán P, Muñoz P, Gregorio Marañón Task Force for Pneumonia (GANG) (2012) Ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus: risk factors and outcome in a large general hospital. J Hosp Infect 80:150–155
8. Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J (2012) Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 54:621–629
9. Dryden MS (2011) Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother Suppl 4:iv7–iv15
10. Pea F, Viale P, Cojutti P, Del Pin B, Zamparini E, Furlanut M (2012) Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother 67:2034–2042
11. Pea F, Furlanut M, Cojutti P, Cristini F, Zamparini E, Franceschi L, Viale P (2010) Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother 54:4605–4610
12. Boselli E, Breilh D, Rimmelé T, Djabarouti S, Toutain J, Chassard D, Saux MC, Allaouchiche B (2005) Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med 33:1529–1533
13. Boselli E, Breilh D, Caillault-Sergent A, Djabarouti S, Guillaume C, Xuereb F, Bouvet L, Rimmelé T, Saux MC, Allaouchiche B (2012) Alveolar diffusion and pharmacokinetics of linezolid administered in continuous infusion to critically ill patients with ventilator-associated pneumonia. J Antimicrob Chemother 67:1207–1210
14. Pea F, Viale P (2006) The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? Clin Infect Dis 15:1764–1771
15. Roberts JA, Lipman J (2009) Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 37:840–851
16. Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J, DALI Study (2014) DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58:1072–1083
17. Roberts JA, Webb S, Paterson D, Ho KM, Lipman J (2009) A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med 37:2071–2078
18. Adembri C, Fallani S, Cassetta MI, Arrigucci S, Ottaviano A, Pecile P, Mazzei T, De Gaudio R, Novelli A (2008) Linezolid pharmacokinetic/pharmacodynamics profile in critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Agents 31:122–129
19. Al-Dorzi HM, Al Harbi SA, Arabi YM (2014) Antibiotic therapy of pneumonia in the obese patient: dosing and delivery. Curr Opin Infect Dis 27:165–173
20. Janson B, Thursky K (2012) Dosing of antibiotics in obesity. Curr Opin Infect Dis 25:634–649
21. Puzniak LA, Morrow LE, Huang DB, Barreto JN (2013) Impact of weight on treatment efficacy and safety in complicated skin and skin structure infections and nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Ther 35:1557–1570
22. Bhalodi AA, Papasavas PK, Tishler DS, Nicolau DP, Kuti JL (2013) Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults. Antimicrob Agents Chemother 57:1144–1149
23. Tsuji Y, Hiraki Y, Matsumoto K, Mizoguchi A, Sadoh S, Kobayashi T, Sakamoto S, Morita K, Yukawa E, Kamimura H, Karube Y (2012) Evaluation of the pharmacokinetics of linezolid in an obese Japanese patient. Scand J Infect Dis 44:626–629
24. Stein GE, Schooley SL, Peloquin CA, Kak V, Havlichek DH, Citron DM, Tyrrell KL, Goldstein EJ (2005) Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother 39:427–432
25. File TM Jr (2010) Recommendations for treatment of hospital-acquired and ventilator-associated pneumonia: review of recent international guidelines. Clin Infect Dis 51(Suppl 1):S42–S47
26. Department of Health and Human Services (2006) Cancer therapy evaluation program, common terminology criteria for adverse events, v.3.0. http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed 9 Aug 2006
27. Dupont WD, Plummer WD (1997) PS power and sample size program version 2.1.3. Control Clin Trials 18:274
28. Fortuna S, De Pascale G, Ragazzoni E, Antonelli M, Navarra P (2013) Validation of a new HPLC-UV method for determination of the antibiotic linezolid in human plasma and in bronchoalveolar lavage. Biomed Chromatogr 27:1489–1496
29. Bobenchik AM, Hindler JA, Giltner CL, Saeki S, Humphries RM (2014) Performance of Vitek 2 for antimicrobial susceptibility testing of Staphylococcus spp. and Enterococcus spp. J Clin Microbiol 52:392–397
30. Craig WA (2003) Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 17:479–501
31. Muzevich KM, Lee KB (2013) Subtherapeutic linezolid concentrations in a patient with morbid obesity and methicillin-resistant Staphylococcus aureus pneumonia: case report and review of the literature. Ann Pharmacother 47:e25
32. Meagher AK, Forrest A, Rayner CR, Birmingham MC, Schentag JJ (2003) Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother 47:548–553